US › Healthcare

Tscan Therapeutics Inc (TCRX)

US · Healthcare · Biotechnology

$0.33+0.76%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Revenue YoY

-65.8%

Net profit

$-30.4M

EPS

$-0.23

EPS estimate

$-0.29

Net margin

-2,888.6%

EPS came in at -0.23 against a street estimate of -0.29 — a beat of 20.7%.

Key statistics

Market cap

$22.4M

Forward P/E

0.0

P/B

0.31

Book value

$1.02

EPS (TTM)

$-0.93

52-week high

$2.57

52-week low

$0.29

50-day MA

$0.75

200-day MA

$0.98

Beta

1.07

Analyst view

Analysts rate Tscan Therapeutics Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $2.67.

Shareholding

Insiders

0.19%

Institutions

62.44%

Largest institutional holders

Fund	Stake
Lynx1 Capital Management, LP	11.83%
Bvf Inc	8.21%
Baker Bros Advisors LP	4.11%
Vanguard Capital Management, LLC	3.18%
BlackRock Inc	2.72%
Renaissance Technologies Corp	2.01%
Deer Management Co. LLC	1.84%
Two Sigma Investments LLC	1.78%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tscan Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.